Partitioning of ifosfamide and its metabolites between red blood cells and plasma

被引:27
作者
Momerency, G
VanCauwenberghe, K
Highley, MS
Harper, PG
VanOosterom, AT
DeBruijn, EA
机构
[1] UNIV ANTWERP,DEPT CHEM,B-2610 ANTWERP,BELGIUM
[2] UNIV ANTWERP,DEPT MED,LAB CANC RES & CLIN ONCOL,B-2610 ANTWERP,BELGIUM
[3] GUYS HOSP,DEPT MED ONCOL,LONDON SE1 9RT,ENGLAND
关键词
D O I
10.1021/js950156a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A recently developed GC-MS analytical method for the quantitative determination of oxazaphosphorines and their metabolites in blood plasma, using stable trifluoroacetyl derivatives and electron capture negative chemical ionization detection, was applied to measure the partitioning of the antitumor drug ifosfamide and its metabolites between plasma and red blood cells for four cancer patients. The separation of a constant volume of red blood cells was performed using a special instrument, MESED, through centrifugation of blood samples. The measured compounds were ifosfamide, 2- and 3-dechloroethylifosfamide, 4-ketoifosfamide, carboxyifosfamide, ifosfamide mustard, 2-chloroethylamine and 1,3-oxazolidin-2-one. Concentration-time profiles for the metabolites in the two blood fractions and partitioning factors between erythrocytes and plasma were obtained. For ifosfamide itself, and metabolites with an intact ring system, a partitioning factor between 1 and 2 was observed for the concentration ratio between red blood cells and plasma in the patients studied. However, for the compounds with an open structure, carboxyifosfamide and ifosfamide mustard, partitioning factors higher than 3 were obtained. The active antitumor metabolite ifosfamide mustard showed a strong preference for the red blood cells in the measured patient samples. This means that erythrocytes may play an important role in the transport and the subsequent release of the active alkylating agent to the tumor cells.
引用
收藏
页码:262 / 265
页数:4
相关论文
共 7 条
[1]  
BLASCHKE G, 1986, ARZNEIMITTEL-FORSCH, V36-2, P1493
[2]   IFOSFAMIDE MESNA - A REVIEW OF ITS ANTINEOPLASTIC ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN CANCER [J].
DECHANT, KL ;
BROGDEN, RN ;
PILKINGTON, T ;
FAULDS, D .
DRUGS, 1991, 42 (03) :428-467
[3]   DESCRIPTION OF AN INSTRUMENT FOR SEPARATION OF RED-CELLS FROM PLASMA AND MEASUREMENT OF RED-CELL VOLUME [J].
DRIESSEN, O ;
HIGHLEY, MS ;
HARPER, PG ;
MAES, RAA ;
DEBRUIJN, EA .
CLINICAL BIOCHEMISTRY, 1994, 27 (03) :195-196
[4]  
HIGHLEY MS, 1995, DRUG METAB DISPOS, V23, P433
[5]  
HIGHLEY MS, 1995, IN PRESS PHARM RES
[6]  
MOMERENCY G, 1994, HRC-J HIGH RES CHROM, V17, P655
[7]   THE DETERMINATION OF CYCLOPHOSPHAMIDE AND ITS METABOLITES IN BLOOD-PLASMA AS STABLE TRIFLUOROACETYL DERIVATIVES BY ELECTRON-CAPTURE CHEMICAL-IONIZATION GAS-CHROMATOGRAPHY MASS-SPECTROMETRY [J].
MOMERENCY, G ;
VANCAUWENBERGHE, K ;
SLEE, PHTJ ;
VANOOSTEROM, AT ;
DEBRUIJN, EA .
BIOLOGICAL MASS SPECTROMETRY, 1994, 23 (03) :149-158